
2Seventy Bio Investor Relations Material
Latest events

Q3 2024
2Seventy Bio

Q1 2025
7 May, 2025

Q4 2024
25 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 2Seventy Bio Inc
Access all reports
2Seventy Bio Inc. (NASDAQ: TSVT) is a biotechnology company specializing in cell and gene therapy with a focus on developing and commercializing treatments for cancer within the United States. The company's research and development efforts are centered on advancing a pipeline of chimeric antigen receptor-T cell (CAR-T) product candidates, including idecabtagene vicleucel (ide-cel or Abecma) and bb21217, aimed at treating multiple myeloma. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
TSVT
Country
🇺🇸 United States